I tend to agree given the somewhat unique territory NEU is working in. Also, there are plenty of commercialised drugs out there worth a lot of money that have average efficacy, but average is considered better than nothing in their cases.
So I think NEU stands in a good position compared to many biotechs tackling competitive areas such as oncology etc. However, if good but not great results occur, I don't think it will put a fire under the SP until any concrete talk of pharma deals eventuate.
FDA meeting is today, page-12
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.65 |
Change
-1.060(6.34%) |
Mkt cap ! $2.000B | |||
| Open | High | Low | Value | Volume |
| $16.61 | $16.65 | $15.54 | $4.955M | 312.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 16679 | $15.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.66 | 54 | 10 |
View Market Depth
| Last trade - 14.48pm 18/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |